Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of sulfasalazine for immune checkpoint inhibitor–related colitis (iRECSA)
jRCTs031210429Completed
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 5-aminosalicylic acid + sulphasalazine in immune-mediated colitis. Primary endpoint: Clinical response at 2 weeks (partial Mayo). Started Apr 2022; status: completed.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
immune-mediated colitis
Beyond the preview
Go deeper on jRCTs031210429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210429.